ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2025
Ovarian Sex Cord Tumor With Annular Tubules (SCTAT) Harbor Recurrent Copy Number Alterations, Including Monosomy 22.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Ultra-rapid peritoneal dissemination of a somatic STK11-mutant adnexal tumor: a case report with molecular correlation and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Sex cord tumor with annular tubules (SCTAT) is a rare ovarian sex cord-stromal neoplasm of low or intermediate malignant potential. Although some SCTATs are associated with Peutz-Jeghers syndrome (PJS), the majority arise in the nonsyndromic setting and typically lack STK11 mutations. As molecular alterations other than STK11 in SCTAT are largely unknown, we sought characterize the genomic landscape in these neoplasms better. SCTATs (n = 22) from 20 patients (5 with PJS, 1 with Prader-Willi syndrome, and 14 with no known syndromic status) were retrospectively identified. STK11 (LKB1) immunohistochemistry (IHC) was performed. Panel-based DNA sequencing was used to detect copy number variations and point mutations in 447 genes in 12 tumors from patients with no history of PJS, with 1 additional non-PJS tumor undergoing only targeted STK11 sequencing. Molecular profiles were compared with other ovarian sex cord-stromal tumors (n = 67). An STK11 mutation and concurrent loss of heterozygosity was in 1 of 13 sporadic tumors. STK11 IHC was intact (n = 14) or equivocal (n = 2) for STK11 wild-type tumors and lost in 1 sporadic tumor with STK11 mutation and 5 tumors from patients with known PJS. TERT promoter mutations were present in 6 of 12 tumors. Recurrent copy number alterations included monosomy 22 (8/12), as well as low-level copy number gains of FOXL2 (10/12; median, 4.3 estimated copies in FOXL2-gained tumors; range, 2.6-7.9), WT1 (9/12), and GATA4 (8/12). One tumor demonstrated biallelic inactivation of TP53 in a region of high-grade transformation characterized by significant cytologic atypia, mitotic activity, and necrosis. In conclusion, nonsyndromic SCTATs are molecularly characterized by FOXL2, WT1, and GATA4 gains, monosomy 22, and TERT promoter mutations. High-grade transformation may rarely occur, a phenomenon not previously described, and is associated with TP53 mutation. STK11 IHC appears to be a reliable surrogate for STK11 mutations and may be useful in suggesting a PJS-related tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.